Cancer immunotherapy / Biotechnology

I currently have two stocks in these categories; one is doing well, and the other, very poorly.

The poor one is Advaxis ticker symbol ADXS. I bought ADXS at $4.82, and today it is at $0.22. That’s right: I’ve lost 95%.


So, having lost so much, is there really much of a reason to liquidate at such a loss? The original idea was that Advaxis had, through research, found some evidence they could use the immune system to fight certain cancers. I don’t think the company is just going to give up. Immunotherapy is working for other cancers. But the problem is that the company could run out of cash before they have a product they can market. But if they keep plugging away, they might finally be able to publish that breakthrough. And then, they should be able to get a good price for their technology.

My other stock is CRISPR Therapeutics AG – ticker symbol CRSP. I bought CRISPR Therapeutics at $20 per share, and today it is at $31.

At one point, six months ago, it was at $70 per share. I should have sold 30% of my shares, and been on a free ride since then. 😉

But really, I still think the technology is good. So I’m not going to lament not-having-cashed-in. Long term, I think I’ll be happy that I still have all my shares.

One of the things though, with this blog, is that if I do get to point of cashing out the purchase price of a stock, I can record that here. In the past, I had cashed out the purchase price of a stock, but then later sold everything when it continued to drop (in the short term). I couldn’t tell, from the view of my holdings that my stock broker gives me, that I was already riding on free money. So I sold. And then the price jumped way up, more than 8x what I bought in for.

Leave a Reply